ABSTRACT
We report the onset of pure red cell aplasia (PRCA) in a patient with a history of polyglandular syndrome including Addison's disease, malabsorption syndrome, diabetes type I and gastric hyperplastic polyposis. An autoimmune origin for this complex disorder was not supported by the presence of organ specific antibodies, but T cells were found to be of polyclonal origin, as demonstrated by molecular analysis of T cell receptor (TCR) gene rearrangement. The pathophysiology of this case, based on laboratory findings and response to therapy, is discussed.
Subject(s)
Autoimmune Diseases/complications , Lymphocytosis/complications , Polyendocrinopathies, Autoimmune/complications , Red-Cell Aplasia, Pure/complications , T-Lymphocytes , Adult , Autoimmune Diseases/drug therapy , Bone Marrow/pathology , Gene Rearrangement, beta-Chain T-Cell Antigen Receptor , Humans , Immunosuppressive Agents/therapeutic use , Lymphocytosis/drug therapy , Malabsorption Syndromes/complications , Malabsorption Syndromes/drug therapy , Male , Polyendocrinopathies, Autoimmune/drug therapy , Red-Cell Aplasia, Pure/drug therapy , Red-Cell Aplasia, Pure/physiopathologyABSTRACT
BACKGROUND AND OBJECTIVE: The best approach to treatment of acute myeloid leukemia (AML) in elderly patients remains controversial. Intensive chemotherapy is the treatment of choice in selected patients, but age related changes might affect the pharmacokinetics of antineoplastic agents resulting in enhanced toxicity. We report our experience in elderly patients treated with idarubicin at attenuated doses plus cytarabine and etoposide. METHODS: Sixty-six AML patients, median age 66, with progressive disease and high tumor burden received idarubicin 8 mg/sqm i.v. d 1,3,5; cytarabine 200 mg/sqm by continuous i.v. infusion d 1-7; etoposide 60 mg/sqm i.v. d 1-5. A second course with the same drugs was planned irrespective of complete remission (CR) achievement. No consolidation was given; 44% had a documented preexisting myelodysplasia, 45% had a documented preexisting myelodysplasia, 45% presented with fever. Promyelocytic leukemias were excluded. RESULTS: Thirty-five patients (53%) achieved CR and 9 PR for an overall response rate of 67%. Nine of them (13%) died early or during the aplastic phase. Preexisting myelodysplasia had no significant impact on CR achievement. Resistant disease was associated with CD7 phenotype and unfavorable karyotype. Overall survival and disease free survival were 14 and 13 months, respectively. The major toxicity consisted of infectious complications (WHO > 2 in 24% of patients). Six patients died for infection, 2 for heart failure, 1 for pulmonary embolism. INTERPRETATION AND CONCLUSIONS: This induction regimen with attenuated doses of idarubicin is feasible and effective, but long-term survival remains an unresolved problem. Alternative post remission approaches are advisable in the aim of improving the remission duration.
Subject(s)
Antibiotics, Antineoplastic/therapeutic use , Idarubicin/therapeutic use , Leukemia, Myeloid/drug therapy , Remission Induction/methods , Acute Disease , Aged , Aged, 80 and over , Female , Humans , Male , Middle AgedSubject(s)
Goiter, Nodular/complications , Hematopoiesis, Extramedullary , Primary Myelofibrosis/pathology , Thyroid Gland/pathology , Aged , Biomarkers/analysis , Biopsy , Calcitonin/analysis , Factor VIII/analysis , Female , Humans , Immunohistochemistry , Primary Myelofibrosis/complications , Thyroid Gland/surgeryABSTRACT
The results of treatment with low dose cytosine arabinoside (LDARA-C) in 131 AML patients ineligible for standard regimens were analyzed retrospectively. Eighty-seven were previously untreated, 25 were refractory to conventional chemotherapy and 19 were relapsed patients. The median age was 66 years (15-84). An antecedent hematological disorder (AHD) was documented in half of the patients. Overall, 22 (17%) achieved complete remission, 14 (11%) partial remission, 77 (59%) had resistant leukemia and 18 died during induction. Median disease free survival was 57 weeks and median survival, for the 87 previously untreated patients, was 22.5 weeks. The prognostic value of initial parameters was analyzed for response. Bone marrow cellularity was the only significant factor. We observed 33% vs 81% (p < 0.01) of responses in patients with normo-hypercellular and hypocellular marrow, respectively. Accordingly, there was a trend to more responses in patients with leukocyte counts of less than 10 x 10(9)/L. M4-M5 FAB subtypes were frequently resistant to LDARA-C, resulting in a lower response rate compared to M0-M2 (18% vs 32%). Other parameters, including age, sex, hemoglobin, platelet count, AHD and fever at diagnosis, had no prognostic value. Our findings suggest that LDARA-C may be an effective treatment for some patients who are not eligible for first line conventional chemotherapy. However, this schedule is not advised in patients with monocytic leukemia or those with an hypercellular marrow.
